trial

Memantine add-on for Cognitive and Negative Symptoms of Schizophrenia

NCTId NCT02001103
as of 2026-07-01
at a glance
Phase 3 · Unknown
Enrollment 120 (estimated)
Primary completion 2016-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Unknown
Enrollment
120 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2014-01
Primary completion
2016-07
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Sponsors

Investigators

1
Chen-Chung Liu, MD, PhDPrincipal Investigator

Sites

1 total
Taipei, Taiwan

Linked catalysts

1

Facts & assertions

4 sourced
Enrollment
120
Phase
PHASE3
Primary Completion Date
2016-07
Status
UNKNOWN
relationships
The graph out of here
drug
indication
indication
indication
investigator